News
RGNX
23.12
+2.48%
0.56
Looking Into Regenxbio's Return On Capital Employed
Benzinga · 11/22 14:50
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:
PR Newswire · 11/22 12:05
5 Analysts Have This to Say About Regenxbio
Benzinga · 11/21 15:04
Morgan Stanley Adjusts Price Target on REGENXBIO to $50 From $52, Maintains Overweight Rating
Morgan Stanley Adjusts Price Target on REGENXBIO to $50 From $52, Maintains Overweight Rating
MT Newswires · 11/21 11:28
What 5 Analyst Ratings Have To Say About Regenxbio
Benzinga · 11/04 13:41
--SVB Securities Adjusts Price Target on REGENXBIO to $14 From $13, Maintains Market Perform Rating
--SVB Securities Adjusts Price Target on REGENXBIO to $14 From $13, Maintains Market Perform Rating
MT Newswires · 11/04 13:14
Chardan Capital Maintains Buy on Regenxbio, Lowers Price Target to $61
Benzinga · 11/04 12:26
--RBC Lowers REGENXBIO's PT to $25 From $29, Keeps Sector Perform, Speculative Risk Rating
--RBC Lowers REGENXBIO's PT to $25 From $29, Keeps Sector Perform, Speculative Risk Rating
MT Newswires · 11/04 09:34
--Chardan Lowers Price Target on REGENXBIO to $61 From $70, Maintains Buy Rating
--Chardan Lowers Price Target on REGENXBIO to $61 From $70, Maintains Buy Rating
MT Newswires · 11/04 08:37
SVB Leerink Maintains Market Perform on Regenxbio, Raises Price Target to $14
Benzinga · 11/04 08:31
--Wedbush Lowers REGENXBIO's Price Target to $18 From $28, Notes Lack of Catalysts Over Next 12 Months; Keeps Neutral Rating
--Wedbush Lowers REGENXBIO's Price Target to $18 From $28, Notes Lack of Catalysts Over Next 12 Months; Keeps Neutral Rating
MT Newswires · 11/04 07:57
Regenxbio Says Diabetic Retinopathy Gene Therapy Shows Meaningful Improvements In Disease Severity
Benzinga · 11/03 16:55
Regenxbio slumps 17% as Q3 Zolgensma royalty revenue falls, net loss widens
Seekingalpha · 11/03 16:21
Regenxbio (RGNX) Reports Q3 Loss, Lags Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -12.90% and 10.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/03 12:45
Recap: Regenxbio Q3 Earnings
Benzinga · 11/03 11:42
Regenxbio GAAP EPS of -$1.75 misses by $0.26, revenue of $26.5M misses by $4.31M
Seekingalpha · 11/03 11:30
BRIEF-Regenxbio Reports Third Quarter 2022 Financial Results And Recent Operational Highlights
Reuters · 11/03 11:24
Regenxbio Q3 EPS $(1.75) Misses $(1.46) Estimate, Sales $26.50M Miss $30.81M Estimate
Benzinga · 11/03 11:09
BRIEF-Regenxbio Presents Positive Interim Data From And The Expansion Of Phase II Altitude Trial Of RGX-314
Reuters · 11/03 10:47
REGENXBIO Presents Interim Data From And The Expansion Of Phase II ALTITUDE Trial Of RGX-314 For The Treatment Of Diabetic Retinopathy Using Suprachoroidal Delivery
Benzinga · 11/03 10:44
More
Webull provides a variety of real-time RGNX stock news. You can receive the latest news about Regenxbio through multiple platforms. This information may help you make smarter investment decisions.
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company focused on providing curative potential of gene therapy. The Company's investigational gene therapies are designed to deliver functional genes to address genetic defects in cells. Its investigational AAV Therapeutics include: RGX-314, which is developing in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases characterized by loss of vision; RGX-202, which is developing to treat Duchenne muscular dystrophy (Duchenne), one of the most common fatal genetic disorders affecting children; RGX-121, RGX-111 and RGX-181, which is developing to treat Mucopolysaccharidosis type II (MPS II), Mucopolysaccharidosis type I (MPS I), and late infantile neuronal ceroid lipofuscinosis type II (CLN2 disease)., and RGX-381, which is developing to treat the ocular manifestations of CLN2 disease.